Molecular diagnostic testing and precision medicine services in the field of gynecology and reproductive health, namely, analysis of patient samples to assess reproductive and gynecologic conditions and their associated systemic health impacts, including diagnostic interpretation that assists in the diagnosis and supports medical management of such conditions; in-clinic and at-home testing with digital monitoring services for medical diagnostic purposes, namely, reporting of physiologic and clinical data for use by reproductive endocrinologists, obstetricians and gynecologists, hospitals, and insurers; all of the foregoing provided exclusively to healthcare providers, payors, and clinical programs, and not including providing general health or wellness education to the public or artificial intelligence-based health screening, imaging, or diagnostic services.

'analysi':17 'artifici':108 'assess':22 'assist':37 'associ':29 'at-hom':52 'base':111 'clinic':50,69,93 'condit':26,47 'data':70 'diagnosi':40 'diagnost':2,34,62,116 'digit':57 'educ':103 'endocrinologist':75 'exclus':87 'field':10 'forego':85 'general':99 'gynecolog':12,25 'gynecologist':78 'health':15,31,100,112 'healthcar':89 'home':54 'hospit':79 'imag':114 'impact':32 'in-clin':48 'includ':33,97 'insur':81 'intellig':110 'intelligence-bas':109 'interpret':35 'manag':44 'medic':43,61 'medicin':6 'molecular':1 'monitor':58 'name':16,64 'obstetrician':76 'patient':19 'payor':91 'physiolog':67 'precis':5 'program':94 'provid':86,90,98 'public':106 'purpos':63 'report':65 'reproduct':14,23,74 'sampl':20 'screen':113 'servic':7,59,117 'support':42 'system':30 'test':3,55 'use':72 'well':102

NURA HEALTH

Owner

Goods & Services